Novavax’s combination vaccine and its Covid-19 vaccine sales for Q1/2022 in Japan are positive drivers for its revenue in the years ahead. More
Articles
Wait for the Dust To Settle Before Buying Roku Stock
What's wrong with ROKU stock? The price isn't right. As the risk that market changes will put pressure on its valuation looms, your best move is to hold off buying it right now. More
eFFECTOR Therapeutics Stock Might Be Worth the Risk in Small Quantities
During the post-SPAC spectacle, EFTR stock be volatile - this should be expected. Still, eFFECTOR's oncology therapies look promising. More
Vinco Ventures Stock Is Overbought, But You Don’t Need to Take a Risk Shorting It
Time to short an overbought BBIG stock in a low-risk fashion as the meme momentum and short squeeze finally subsides More
Authentic Brands Is the Most Fascinating IPO of the Year
Expect Shaquille O'Neal to ring the bell when Authentic Brands goes public this fall to become AUTH stock. Then expect to be entertained. More
